About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

Proadrenomedullin and Microcirculation in Monitoring Organ Dysfunction in Patient With Infection

Clinicaltrials.gov identifier NCT03931967

Recruitment Status Completed

First Posted April 30, 2019

Last update posted July 18, 2019

Study Description

Brief summary:

This study evaluates the association between plasmatic levels of Mid Regional Proadrenomedullin (MR-proADM) and the sublingual microcirculation in critical care patients admitted with infection, sepsis or septic shock.

  • Condition or Disease:Infection
    Sepsis
    Septic Shock
  • Intervention/Treatment: Diagnostic Test: MR-proADM
  • Phase: N/A
Detailed Description

MR-proADM (Mid Region proAdrenomedullin) is a fragment of 48 amino-acids of ADM (Adrenomedullin), a protein belonging to the super-family of calcitonin-related peptides. MR-proADM is released in a 1:1 ratio with its native protein ADM. Blood levels of ADM are high in several conditions including infection, sepsis of septic shock. MR-proADM seems to be a promising marker for early diagnosis, prognosis and mortality in sepsis and it is also related to sepsis-induced organ failure. The microcirculatory and endothelial damages represent two corner stones of the sepsis pathophysiology. They involved the loss of functional capillaries density and the loss of red blood cells deformability, the endothelial cell disfunction induced by sepsis, the induction of the apoptosis and necrosis, the alteration in the capillary permeability due to the loss of vasomotor tone and control. Moreover sepsis is characterised by the increased levels of adhesion molecules and the consequent interaction between neutrophils and endothelium, the fibrin deposition and the activation of the coagulation. The aim of the study is to evaluate the correlation between the alteration in microcirculation and the levels of MR-proADM. MFI (Microvascular Flow Index) is a qualitative measurement of microcirculation and the microcirculatory alterations during sepsis are crucial in the pathophysiology of this syndrome. It is related to prognosis and mortality in patient with sepsis in ICU (Intensive Care Unit) Studying the relations between MFI and MR-proADM in the first five days of ICU stay could represent a good way to connect the pathophysiological background to a laboratory marker for an early diagnosis and for a measure of prognosis in patient with infections. It is also important to compare the levels of MR-proADM with the other microcirculatory parameters (Total Vessel Density, Perfused Vessels Density, Percentage of Perfused Vessels, DeBacker score, Flow Heterogeneity index) and with the parameters of glycocalix and endothelial disfunction (Perfused Boundary Region and Endothelin-1) When inclusion criteria are present and there are no exclusion criteria, patients will be enrolled for this five-days long study. Informed consent will be taken from the patient before enrollment or from the legal representative but when the neurological conditions do not allow At the beginning of the study anthropometric data will be collected together with the main clinical and laboratory parameters (systolic, diastolic and mean arterial pressure, heart rate, mechanical ventilation parameters, blood gas parameters, vasoactive therapy, main parameters for renal, hepatic and haematological function, infectious condition and cultures). Arterial blood samples will be collected and blood will be immediately centrifuged and plasma and serum samples will be stored at -80°C for the measurement of MR-proADM and Endothelin-1. Moreover at the beginning of the study, the day after and the fifth days from the enrolment, the main microcirculatory parameters will be taken through Incident Dark Field Technology. Glycocheck Technology will be used to collect glycocalix conditions.

Study Design
  • Study Type: Observational
  • Actual Enrollment: 21 participants
  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Official Title: Proadrenomedullin and Microcirculation in Monitoring Organ Dysfunction in Patient With Infection: Prospective Observational Study
  • Actual Study Start Date: November 2018
  • Actual Primary Completion Date: June 2019
  • Actual Study Completion Date: June 2019
Groups and Cohorts
Groups/Cohorts Intervention/treatment
: MR-proADM
Diagnostic Test: MR-proADM
to evaluate the plasmatic level of MR-proADM and endothelin-1 in the first five days of ICU stay.
Outcome Measures
  • Primary Outcome Measures: 1. Assessment of Microvascular Flow Index (MFI) [ Time Frame: Five days ]
    Correlation between plasmatic value of MR-proADM and variation in Microvascular Flow Index (MFI) in patients admitted in ICU with suspected infection. MFI is detected in vivo by Incident Dark Field (IDF) Imaging at sublingual microcirculation. It represents the quality of blood flow at microcirculatory level.
  • 2. Assessment of the concentration of Mid Regional Proadrenomedullin (MR-proADM) [ Time Frame: Five days ]
    Correlation between plasmatic value of MR-proADM and variation in Microvascular Flow Index (MFI) in patients admitted in ICU with suspected infection. Mid Regional Proadrenomedullin (MR-proADM, unity of measurement nmol/L) is measured through a specify immunoenzymatic assay. MR-proADM is a diagnostic and prognostic marker of infection and sepsis.
  • Secondary Outcome Measures: 1. Cut-off for Microvascular Flow Index (MFI) based on Mid Regional Proadrenomedullin (MR-proADM) levels [ Time Frame: Five days ]
    Founding a MR-proADM cut-off which would be able to predict a variation in MFI in patients admitted in ICU with suspected infection.
  • 2. Assessment of patient's mortality [ Time Frame: Five days ]
    Correlation between mortality (in percentage) and plasmatic levels of MR-proADM, based on MR-proADM clearance.
  • 3. Assessment of new organ failure [ Time Frame: Five days ]
    Correlation between organ failures and MRproADM, based on daily calculation of Sequential Organ Failure Assessment Score(SOFA score, 0 best value up to 24 worst value).Score subscales:Respiratory(PaO2/FiO2 (mmHg)≥ 400,score 0,< 400,+1,< 300, +2,< 200 and mechanically ventilated,+3,< 100 and mechanically ventilated,+4);Nervous(Glasgow coma scale 15,score 0,13-14,+1,10-12 +2,6-9 and mechanically ventilated,score +3,<6,+4);Cardiovascular(Mean arterial pressure/vasopressors:MAP≥70 mmHg,score 0,MAP<70 mmHg,+1,dopamine≤5 µg/kg/min or dobutamine (any dose),+2,dopamine>5 µg/kg/min OR epinephrine≤0.1 µg/kg/min OR norepinephrine≤ 0.1µg/kg/min,+3,dopamine>15 µg/kg/min OR epinephrine>0.1µg/kg/min OR norepinephrine>0.1µg/kg,+4);Liver(Bilirubin(mg/dl)[μmol/L],< 1.2[< 20],score 0,1.2-1.9[20-32],+1,2.0-5.9[33-101], +2,6.0-11.9[102-204],+3,> 12.0[> 204],+4);Kidney(Creatinine (mg/dl)[μmol/L] < 1.2[< 110],score 0,1.2-1.9[110-170],+1,2.0-3.4[171-299],+2,3.5-4.9[300-440],+3,> 5.0[> 440], +4),Coagulation
  • 4. Assessment of Procalcitonine (PCT) [ Time Frame: Five days ]
    Correlation between PCT (Unity of measurement, ng/ml) and MR-proADM as combined score for outcome measurement in term of mortality.
  • 5. Assessment of other microcirculatory parameters in patient with sepsis or septic shock. [ Time Frame: Five days ]
    Correlation between plasmatic value of MR-proADM and variation in Perfused Vessels Density (PVD, unity of measure 1/mm), Percentage of Perfused Vessels (PPV, unity of measure %), Total Vessels Density (TVD, unity of measure mm/mm2), Flow Heterogeneity Index (FHI), DeBacker Score (unit of measure, 1/mm). The parameters are detected in vivo by Incident Dark Field (IDF) Imaging at sublingual microcirculation. MR-proADM is a diagnostic and prognostic marker of infection and sepsis.
  • 6. Mid Regional Proadrenomedullin (MR-proADM) in patient with difference infectious condition. [ Time Frame: Five days ]
    Comparison of the MR-proADM blood concentration (nmol/L) in patient with suspected infection, infection, sepsis and septic shock.
  • 7. Correlation between Mid Regional Proadrenomedullin (MR-proADM) and glycocalix and endothelial damage. [ Time Frame: Five days ]
    Association between plasmatic value of MR-proADM and variation in Perfused Boundary Region (PBR, the parameters is detected in vivo by Sidestream Dark Field (SDF) Imaging at sublingual microcirculation) and Endothelin-1. MR-proADM is a diagnostic and prognostic marker of infection and sepsis.
  • Biospecimen Retention: Samples Without DNA

    Dosage of MicroMRproADM, endothelin-1

Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: 20 patients with suspected infection, infection, sepsis or septic shock admitted to ICU
Criteria

Inclusion Criteria:

- Suspected Infection, Infection, Sepsis or Septic Shock in patient admitted in ICU from
no more than 24 hours and which have previously monitored blood pressure and have a
central venous catheter in place.

Exclusion Criteria:

- Age 24 hours;

- Length of stay in other hospital unit, ward or surgery > 48 hours;

- Refusal of informed consent;

- Conditions that do not allow the possibility of getting a monitoring of sublingual
microcirculation (maxillofacial trauma, serious inability to jaw, copious blood loss
or secretions from the mouth)

Contacts and Locations
Contacts
Locations

Italy
AOU Ospedali Riuniti Ancona - Università Politecnica delle Marche
Ancona

Sponsors and Collaborators

Università Politecnica delle Marche

Investigators

Principal Investigator: Abele Donati, MD, PhD UNIVERSITA' POLITECNICA DELLE MARCHE

More Information
  • Responsible Party: Università Politecnica delle Marche
  • ClinicalTrials.gov Identifier: NCT03931967 History of Changes
  • Other Study ID Numbers: MicroMRproADM
  • First Posted: April 30, 2019 Key Record Dates
  • Last Update Posted: July 18, 2019
  • Last Verified: April 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Università Politecnica delle Marche: Sepsis
    Septic shock
    Microcirculation
    Glycocalix
    Proadrenomedullin
    Organ dysfunction
    Critical Care
    Intensive Care
  • Additional relevant MeSH terms: Infection
    Communicable Diseases
    Shock, Septic